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Herpesviruses are large, enveloped DNA
viruses.There are currently 8 known
human herpesviruses and 1 primate
species that is a rare human pathogen.
Most people have been infected with sev-
eral human herpesviruses. In immuno-
competent individuals primary infections
with herpesviruses are generally mild, self-
limiting infections. After primary infec-
tion, herpesviruses remain latent in either
sensory nerve ganglia or immune cells.
Latency may persist indefinitely unless
immune suppression develops, in which
case recurrent disease can become life-
threatening. In the immunocompetent
patient, clinical recurrences that are
milder than the primary infection are the
hallmark of herpesvirus infections.
This article focuses on the role of antiviral
therapy of common, treatable human her-
pesviruses — herpes simplex virus (HSV),
varicella zoster virus (VZV) and
cytomegalovirus (CMV). It is important
to recognise that currently available antivi-
ral therapy is unable to cure infection
(latency persists after therapy) and has
relatively modest clinical benefit.
ANTIVIRAL DRUGS
Aciclovir is a nucleoside analogue of
guanosine. In infected cells it is activated
to the active phosphorylated form by the
viral thymidine kinase enzyme. Aciclovir
has activity against HSV and VZV. Higher
doses of aciclovir are required to treat
VZV, as it is less sensitive. Aciclovir is well
tolerated, although renal dysfunction may
occur with high intravenous doses. It is
available in parenteral, topical and oral
formulations, but is poorly absorbed oral-
ly. Valaciclovir (a pro-drug of aciclovir)
and famciclovir (also a nucleoside ana-
logue of guanosine) have better absorp-
tion, allowing less frequent dosing inter-
vals.
Ganciclovir, another guanosine analogue,
is used to treat serious CMV infection
almost exclusively in immunocompro-
mised patients. It causes significant bone
marrow suppression. Foscarnet and cido-
fovir (not registered in South Africa) are
alternatives to ganciclovir for CMV infec-
tion and are useful for aciclovir-resistant
HSV infections. Ganciclovir, foscarnet
and cidofovir should be used only by spe-
cialists in infectious diseases or transplan-
tation.
HERPES SIMPLEX INFECTIONS
There are two HSVs — types 1 and 2.
Type 1 typically produces disease of the
mouth or lips, whereas type 2 produces
genital lesions. However, genital infection
with type 1 is becoming more common
because of the widespread practice of oral
sex. Similarly, oral infection caused by
type 2 also occur s. When type 1 infections
affect the genitals the disease is milder
and recurrences less frequent.The com-
monest indication for antiviral therapy in
adults is genital herpes, whereas in chil-
dren it is herpes stomatitis. Recommen-
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Antiviral therapy in herpes-
virus infections
Herpesviruses are commonly seen in clinical
practice. This article discusses their management
in some detail.
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After primary infection,
herpesviruses remain
latent in either sensory
nerve ganglia or immune
c e l l s .
ded doses, administration and
duration of therapy for HSV infec-
tions are given in Table I.
Primary HSV infection
Primary infection with either HSV
type 1 or 2 (Fig. 1) affects a fairly
extensive mucocutaneous area and
is often accompanied by consider-
able discomfort, fever and tender
enlargement of the draining lymph
nodes. A typical primary attack
lasts about 10 - 14 days. Although
primary infections are self-limiting
and complications uncommon, the
morbidity is significant. Antiviral
therapy is effective for primary
infection, but it has no effect what-
soever on the subsequent rate of
recurrences.
Recurrent HSV
After a primary infection, clinically
apparent recurrent attacks occur in
most cases. Recurrences are
derived from a latent reservoir
inside nerve tissue of the patient
and not from external re-infection.
Clinical recurrences are much
milder infections affecting a small
area and lasting a few days (the
typical ‘cold sore’).The frequency
of recurrences is highly variable,
with about one-third of patients
experiencing frequent attacks. Over
years the frequency of recurrences
decreases. Antiviral therapy is of
minimal clinical benefit in recur-
rent disease. Oral therapy must be
commenced within 24 hours of
onset of the recurrence to have an
effect. Even then, the duration of
clinical disease is reduced by only
1 day. Topical therapy has been
shown to have no clinical benefit in
recurrent disease. Antiviral therapy
is seldom indicated for recurrent
herpes labialis. Avoiding exposure
to ultraviolet light substantially
reduces the incidence of this con-
dition.
Patients who suffer frequent recur-
rences of genital herpes (≥ 6 a
year) should be considered for pro-
phylactic antiviral therapy, which
should be given for 6 months and
possibly longer (Table I). In
immunocompetent subjects the
development of resistance to aci-
clovir is very rare. A further benefit
of prophylaxis is the reduction in
viral shedding, including shedding
in the absence of  lesions or symp-
toms, which is more pervasive
than shedding associated with visi-
ble lesions. It is estimated that
most cases of initial infection are
acquired from people who do not
have overt herpes lesions.
Promoting condom use is the most
cost-effective strategy to prevent
HSV transmission.
Women with recurrent or primary
genital HSV at the time of delivery
can transmit HSV to the neonate,
which can cause severe disease.
Caesarean section before mem-
brane rupture is recommended to
prevent neonatal HSV where the
mother has acquired HSV infec-
tion in the third trimester of preg-
nancy, but the management of
women with recurrent HSV in late
pregnancy is controversial, since
the risk for the baby is much lower.
Aciclovir appears to be safe in
pregnancy. Trials of prophylactic
aciclovir have shown a reduction in
recurrence and viral shedding in
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Clinical syndrome Antiviral dose and administration Duration Notes
Primary HSV Aciclovir 400 mg 8 hourly 10 days May need initial
Valaciclovir 500 mg 12 hourly parenteral therapy
Famciclovir 250 mg 8 hourly
Recurrent HSV Aciclovir 400 mg 8 hourly 5 days Commence within 24
Valaciclovir 500 mg 12 hourly hours. Minimal
Famciclovir 125 mg 12 hourly clinical benefit
Mucocutaneous HSV — Aciclovir 400 mg 8 hourly 10 days Higher doses may be
immunocompromised Valaciclovir 500 mg 12 hourly necessary
Famciclovir 125 mg 12 hourly
Frequent recurrences Aciclovir 400 mg 12 hourly 6 months May need repeated
of genital HSV Valaciclovir 250 mg 12 hourly courses
Famciclovir 250 mg 12 hourly
Ocular HSV Aciclovir ointment 5 times daily 5 - 10 days Ophthalmologist 
referral essential
Life-threatening HSV Aciclovir 5 - 10 mg/kg 8 hourly IV 14 days Use higher dose for 
encephalitis
Note that antiviral therapy is of minimal clinical benefit in some circumstances (e.g. recurrent HSV in immunocompetent individuals). 
IV = intravenously.
Table I. Recommendations for treating HSV infections (adult doses) 
Fig. 1. Primary genital herpes is often
extensive. Antiviral therapy will shorten
the course of the illness, but has no
effect on subsequent recurrences.
pregnant women.There is contra-
dictory evidence from clinical trials
regarding the effect of prophylactic
aciclovir on caesarean section rates.
HSV ocular infection
HSV can cause primary infection
involving the eye, with follicular
conjunctivitis, vesicles on the eye-
lids and regional adenopathy.
Corneal ulceration is common.
Herpes simplex keratitis caused by
recurrent HSV is more common. It
typically results in a dendritic
corneal ulcer. Topical aciclovir is
effective for superficial ocular HSV
infections. All cases should be fol-
lowed up by an ophthalmologist.
Mucocutaneous HSV in immuno-
compromised patients
Patients with eczema can develop
extensive, cutaneous HSV, i.e.
eczema herpeticum (Fig. 2). The
commonest mucocutaneous mani-
festation of HSV in patients with
impaired cellular immunity is
chronic ulceration, typically in the
anogenital area (Fig. 3).When
these ulcers persist for 4 weeks or
more in HIV-infected individuals
the disease is considered AIDS-
defining. Chronic HSV ulceration
is one of the more common AIDS-
defining illnesses in southern
Africa and is frequently misdiag-
nosed. Less commonly, HSV can




The two commonest life-threaten-
ing HSV infections are encephalitis
and disseminated neonatal disease.
Disseminated disease can occur in
immunocompromised patients, and
also rarely in pregnant women and
immunocompetent persons, in
whom the diagnosis is often
missed. Intravenous aciclovir is




Aciclovir resistance is rare. It gen-
erally occurs in immunocompro-
mised patients given prolonged or
repeated courses of the drug. It is
caused mainly by thymidine
kinase-deficient virus mutants that
are less fit than the ‘wild type’
HSV (therefore resistance can be
reversed if therapy is stopped).
Aciclovir-resistant mutants are also
resistant to valaciclovir and famci-
clovir. Foscarnet or cidofovir are
effective if there is aciclovir resis-
tance, but both have significant
side-effects and should be used




Primary infection with VZV results
in chickenpox. Latent infection in
nerve ganglia follows chickenpox,
and disease may recur decades
later in the form of a painful vesic-
ular eruption in a dermatomal dis-
tribution known as shingles. A vari-
ety of neurological syndromes due
to VZV have been described in
immunocompromised patients, and
less often  in immunocompetent
patients. Recommended doses,
administration and duration of
therapy for VZV infections are
given in Table II.
Chickenpox (varicella)
Antiviral therapy is of very limited
benefit in otherwise healthy
patients with chickenpox.Therapy
should be started within 24 hours
of onset, which shortens the dura-
tion of the illness by only 1 - 2
days.The complication rate and
mortality of chickenpox is generally
low, but is highest in adults.
Therefore it may be reasonable to
offer antiviral therapy in adults.
Chickenpox in immunocompro-
mised patients, especially those
with leukaemia, is severe and may
be life-threatening.The common-
est life-threatening complication of
chickenpox in immunocompetent
patients is pneumonia (Fig. 4),
which occurs in 1 - 2% of adults
with chickenpox. Smoking and
pregnancy are risk factors for the
development of chickenpox pneu-
monia. In life-threatening chicken-
pox antiviral therapy is mandatory
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Fig. 2. Extensive, cutaneous HSV
infection can occur in patients with
eczema. Antiviral therapy is neces-
sary.
Fig. 3. Chronic mucocutaneous HSV
ulceration is a common manifestation
of advanced HIV disease.
and should be given intravenously.
There is no good evidence to sup-




The course of shingles in immuno-
competent patients (Fig. 5) is
shortened by about 2 days if antivi-
ral therapy is commenced within
72 hours of onset. Acute pain is
dramatically shortened, but it is
unclear if the subsequent develop-
ment of postherpetic neuralgia is
modified by antiviral therapy.
In immunocompromised patients
shingles is more prolonged and
may be multidermatomal. Antiviral
therapy should be strongly consid-
ered in immunocompromised
patients even if they present more
than 72 hours after onset. Shingles
with dissemination (Fig. 6) may
also occur in immunocompromised
patients, in which cases intra-
venous aciclovir is mandatory.
Neurological VZV complications
in immunocompromised patients
VZV can cause a myelopathy or a
small vessel encephalitis in
immunocompromised patients.
Both can present without a rash
and diagnosis is made by a nucleic
acid amplification test (usually the






primary CMV is subclinical or
causes a mild glandular fever-type
illness. Serious complications are
rare. Antiviral therapy for CMV
has serious side-effects, conse-
quently there is virtually never a
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Clinical syndrome Antiviral dose and administration Duration Notes
Chickenpox Aciclovir 800 mg 5 times/day 7 days Commence therapy within
Valaciclovir 1 g 8 hourly 24 hours of onset — illness
Famciclovir 250 mg 8 hourly shortened 1 - 2 days
Shingles Aciclovir 800 mg 5 times/day 7 days Commence within 72
Valaciclovir 1 g 8 hourly hours (except in immune-
Famciclovir 250 mg 8 hourly suppressed patients). 
Consider parenteral 
aciclovir if sight is
threatened





IV =  intravenously.
Table II. Recommendations for treating VZV infections (adult doses) 
Fig. 4. Chickenpox pneumonia is a
life-threatening complication — intra-
venous aciclovir is mandator y.
Fig. 5. Shingles involving the oph-
thalmic branch of the left trigeminal
nerve. This patient presented 5 days
after onset, too late to benefit from
antiviral therapy.
Fig. 6. Multidermatomal shingles with
dissemination in a patient with lym-
phoma. Intravenous aciclovir was
administered and she made an
uneventful recovery.
role for antiviral therapy in this set-
ting.
In contrast, patients with impaired
cellular immunity (e.g. AIDS,
immunosuppressant drugs) experi-
ence life-threatening disease involv-
ing tissues outside the reticulo-
endothelial system, or develop
sight-threatening CMV retinitis.
Most disease is caused by reactiva-
tion of latent CMV infection.
Intravenous ganciclovir is the drug
of choice for initial therapy of
CMV disease in immunocompro-
mised patients. Unless immunity
can be improved (e.g. reducing
dose of immunosuppressants in
transplant recipients or using high-
ly active antiretroviral therapy in
AIDS patients), maintenance ther-
apy with lower dose intravenous
ganciclovir or oral ganciclovir (or
its pro-drug valganciclovir) is
required to prevent recurrent
CMV disease.
Prevention of CMV disease can be
achieved in transplant recipients by
either pre-emptive therapy of sub-
clinical reactivation (diagnosed by
increasing levels of antigenaemia or
rising CMV viral load) or prophy-
laxis (especially with a seronegative
recipient and seropositive donor).
Ganciclovir is generally used for
prophylaxis.
Treatment and prophylaxis of
CMV disease in immunocompro-
mised patients are highly spe-
cialised and should be undertaken
only by infectious disease or trans-
plant specialists.
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IN A NUTSHELL
Antiviral therapy for primary HSV
infection has no effect on the
subsequent rate of recurrences.
Antiviral therapy is of minimal
clinical benefit for recurrent HSV
infection in immunocompetent
persons.
Patients who suffer frequent
recurrences  of genital herpes ((≥
6 a year) should be considered
for prophylactic antiviral therapy
for 6 months.
Avoiding exposure to ultraviolet
light substantially reduces the
incidence of recurrent herpes
labialis.
Chronic HSV ulceration is one of
the more common AIDS-defining
illnesses in southern Africa and is
frequently misdiagnosed.
Antiviral therapy is of very limited
benefit in otherwise healthy
patients with chickenpox.
In life-threatening HSV or VZ V
infections intravenous aciclovir is
mandatory.
Antiviral therapy must be com-
menced within 72 hours of onset
in immunocompetent patients
with shingles.
Antiviral therapy for CMV has vir-
tually no place in the manage-




Whole grain cereals and
health
Yet more evidence linking whole
grain cereals to a longer, healthi-
er life appeared in the American
Journal of Clinical Nutrition in
March this year (2003; 77: 594-
599).The data show that male
doctors who eat whole grain
cereals for breakfast are less like-
ly to die from cardiovascular dis-
ease — in fact less likely to die
from anything  — than col-
leagues who eat refined cereals
instead.The effect is moderate,
but probably real.The
researchers accounted for all the
usual confounders.
